Abstract
Anorexia nervosa (AN) is a complex psychiatric disorder with high morbidity and mortality rates. While many individuals make full recoveries, up to a third of patients develop a chronic, treatment-resistant form of the illness that leads to a premature death in 15-20% of those affected. There have been few advances in treatment, both in terms of psychological or pharmacologic treatment over the last 30 years. Food aversion is commonly cited by patients with AN as a barrier to normalizing eating and weight. Our group has a keen interest in examining factors that might allow this to be addressed, thus improving treatment outcomes through personalized dietary plans or nutritional supplementation related to underlying genetic status.
Original language | English (US) |
---|---|
Journal | Prostaglandins and Other Lipid Mediators |
DOIs | |
State | Accepted/In press - 2017 |
Keywords
- Anorexia nervosa
- Eicosanoid
- Inflammation
- Mental health
- Polyunsaturated fatty acid
- Weight and appetite
ASJC Scopus subject areas
- Physiology
- Biochemistry
- Pharmacology
- Cell Biology